Skip to content
value.today

Prolacta Bioscience Inc.

Total raised
$65 M
4 rounds on record
Latest round
$9 M
May 2018
First round on record
Jun 2011
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Prolacta Bioscience Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$9 MNo. 4$2 to $10 million

Prolacta Bioscience Inc.: Raise no. 4, May 2018

Investors in this round

11 investors had bought by the notice of May 14, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Kofsky · Executive Officer
  • Alyson Fuller · Executive Officer
  • David Dreyer · Executive Officer
  • John Shields · Executive Officer
  • Joseph Fournell · Executive Officer
  • Mark Hannon · Executive Officer
  • Martin Lee · Executive Officer
  • Scott Eaker · Executive Officer
  • Scott Elster · Executive Officer, Director
  • Victoria Niklas · Executive Officer
  • Vincent Gaspar · Executive Officer
  • Dan Janney · Director
  • David Brailer · Director
  • Ernie Strapazon · Director
  • Frank Foster · Director
  • John Bacich Jr. · Director
  • Martin Sutter · Director
  • Sally Crawford · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John M. Shields, General Counsel & Secretary. Source: SEC Form D, newest notice filed May 14, 2018. Read the notice at the SEC.

equity, optionsSEC
Nov 2016$35 MNo. 3$10 to $50 million

Prolacta Bioscience Inc.: Raise no. 3, Nov 2016

Investors in this round

4 investors had bought by the notice of Dec 9, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John M. Shields · Executive Officer
  • Scott Elster · Executive Officer, Director
  • Dan Janney · Director
  • David Brailer · Director
  • Ernie Strapazon · Director
  • Frank Foster · Director
  • John Bacich, Jr. · Director
  • Martin Sutter · Director
  • Ned Brown · Director
  • Sally Crawford · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John M. Shields, General Counsel & Secretary. Source: SEC Form D, newest notice filed Dec 9, 2016. Read the notice at the SEC.

equitySEC
Oct 2011$15 MNo. 2$10 to $50 million

Prolacta Bioscience Inc.: Raise no. 2, Oct 2011

Investors in this round

2 investors had bought by the notice of Nov 2, 2011: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Scott Elster · Executive Officer, Director
  • Tami Ciranna · Executive Officer
  • Alison Kiley · Director
  • Ernie D. Strapazon · Director
  • Frank D. Foster · Director
  • John D. Bacich, Jr. · Director
  • Joshua D. Saipe · Director
  • Ned D. Brown · Director
  • Sally Crawford · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott A. Elster, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 2, 2011. Read the notice at the SEC.

equitySEC
Jun 2011$6 MNo. 1$2 to $10 million

Prolacta Bioscience Inc.: Raise no. 1, Jun 2011

Investors in this round

20 investors had bought by the notice of Aug 9, 2011: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Scott A. Elster · Executive Officer, Director
  • Tami A. Ciranna · Executive Officer
  • Alison A. Kiley · Director
  • David H. Cremin · Director
  • Ernie H. Strapazon · Director
  • Frank H. Foster · Director
  • John H. Bacich · Director
  • Stephen H. Watkins · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott A. Elster, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 9, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Prolacta Bioscience Inc. chose not to state its revenue in its newest notice of a funding round (May 2018).

    SEC Form D · May 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2018

That is all the official record says: Prolacta Bioscience Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Prolacta Bioscience Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Prolacta Bioscience Inc.
NameRoleNamed in
Alan KofskyExecutive officerMay 2018
Alyson FullerExecutive officerMay 2018
David DreyerExecutive officerMay 2018
John ShieldsExecutive officerMay 2018
Joseph FournellExecutive officerMay 2018
Mark HannonExecutive officerMay 2018
Martin LeeExecutive officerMay 2018
Scott EakerExecutive officerMay 2018
Scott ElsterExecutive officerMay 2018
Victoria NiklasExecutive officerMay 2018
Vincent GasparExecutive officerMay 2018
John M. ShieldsExecutive officerDec 2016
Tami CirannaExecutive officerNov 2011
Scott A. ElsterExecutive officerAug 2011
Tami A. CirannaExecutive officerAug 2011
Dan JanneyDirectorMay 2018
David BrailerDirectorMay 2018
Ernie StrapazonDirectorMay 2018
Frank FosterDirectorMay 2018
John Bacich Jr.DirectorMay 2018
Martin SutterDirectorMay 2018
Sally CrawfordDirectorMay 2018
Scott ElsterDirectorMay 2018
John Bacich, Jr.DirectorDec 2016
Ned BrownDirectorDec 2016
Alison KileyDirectorNov 2011
Ernie D. StrapazonDirectorNov 2011
Frank D. FosterDirectorNov 2011
John D. Bacich, Jr.DirectorNov 2011
Joshua D. SaipeDirectorNov 2011
Ned D. BrownDirectorNov 2011
Alison A. KileyDirectorAug 2011
David H. CreminDirectorAug 2011
Ernie H. StrapazonDirectorAug 2011
Frank H. FosterDirectorAug 2011
John H. BacichDirectorAug 2011
Scott A. ElsterDirectorAug 2011
Stephen H. WatkinsDirectorAug 2011